{"organizations": [], "uuid": "b83192530e7e99cbe89ad310c9b9126ef41501c6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180419.html", "section_title": "Archive News &amp; Video for Thursday, 19 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/lilly-fda/fda-staff-cites-safety-issues-for-lilly-incytes-rheumatoid-arthritis-drug-idUSL3N1RW4SO", "country": "US", "domain_rank": 408, "title": "FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.016, "site_type": "news", "published": "2018-04-19T20:17:00.000+03:00", "replies_count": 0, "uuid": "b83192530e7e99cbe89ad310c9b9126ef41501c6"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/lilly-fda/fda-staff-cites-safety-issues-for-lilly-incytes-rheumatoid-arthritis-drug-idUSL3N1RW4SO", "ord_in_thread": 0, "title": "FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug", "locations": [], "entities": {"persons": [{"name": "anil d’silva", "sentiment": "none"}, {"name": "tamara mathias", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "incyte", "sentiment": "negative"}, {"name": "lilly", "sentiment": "negative"}, {"name": "eli lilly and co", "sentiment": "none"}, {"name": "incyte corp", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19 (Reuters) - The U.S. Food and Drug Administration staff on Thursday flagged concerns about potentially fatal blood clots from higher doses of Eli Lilly and Co and Incyte Corp’s rheumatoid arthritis drug.\nAn independent panel of experts will hold an advisory committee meeting on Monday to assess the drug based on data from its developers and the analysis by FDA staff. (Reporting by Tamara Mathias in Bengaluru; Editing by Anil D’Silva)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T20:17:00.000+03:00", "crawled": "2018-04-20T11:40:50.015+03:00", "highlightTitle": ""}